Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

This FOA provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological disorders that fall under the NINDS mission. Therapeutic agents may include but are not limited to small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the NINDS Cooperative Research to Enable and Advance Translational Enterprises for Biologics program (CREATE Bio) program for biologics, biotechnology products, Blueprint Neurotherapeutics Network for small molecules, or other translational programs.

Companion FOAs:

PAR-18-762R61/R33 Phased Innovation Award
PAR-18-763R61/R33 Phased Innovation Award


  • Application Due Dates: June 19, 2018, October 17, 2018, February 20, 2019, June 19, 2019, October 17, 2019, February 19, 2020, June 17, 2020, October 20, 2020 and February 17, 2021
  • AIDS Due Dates: Jan. 7, May 7, Sep. 7

PAR-18-761 Expiration Date May 8, 2021

Agency Website



Amount Description

Direct costs cannot exceed $499,000 in any one year . Cumulative direct costs for the entire 3-year project period may not exceed $750,000.

Funding Type





Engineering and Physical Sciences
Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

October 20, 2020